First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Osimertinib, Osimertinib Plus Chemotherapy, and Amivantamab Plus Lazertinib with Focus on Efficacy, Safety, Acquired Resistance, and Health-Economic Considerations

Background: Treatment of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) has evolved from first-generation tyrosine kinase inhibitors (TKIs) to third-generation osimertinib and, more recently, to intensified first-line regimens. Osimertinib monotherapy remains effective and comparatively tolerable, while osimertinib plus platinum-pemetrexed and amivantamab plus lazertinib improve progression-free and overall survival at the cost of greater toxicity. This article evaluates current first- and subsequent-line treatment strategies for advanced NSCLC harboring common sensitizing EGFR mutations (exon 19 deletions or exon 21 L858R substitutions), with particular attention to efficacy, toxicity, resistance mechanisms, and patient selection. Methods: A structured assessment of phase III randomized trials, published network meta-analyses and indirect comparisons, and resistance-focused literature was conducted to compare efficacy, toxicity, resistance mechanisms, costs, and patient-selection considerations across current treatments. No original statistical analysis was performed; comparative estimates were derived from published studies. Results: First-line intensification with osimertinib plus chemotherapy or amivantamab plus lazertinib improves progression-free survival (PFS) and overall survival (OS) over osimertinib alone in EGFR-mutant NSCLC, particularly in high-risk patients, but it also increases toxicity, and resistance remains heterogeneous and may require repeat molecular profiling to guide further therapy. Published indirect comparisons have not shown a significant difference between the two intensified regimens. Conclusions: No single regimen suits all patients. Fit patients with high-risk features may derive the greatest absolute benefit from first-line intensification. Apparent differences between osimertinib plus platinum-pemetrexed and amivantamab plus lazertinib in subgroups (such as L858R or TP53 co-mutation) are based mainly on exploratory cross-trial data and do not establish superiority of either regimen. Amivantamab plus lazertinib offers a chemotherapy-free alternative with a distinct toxicity profile. Osimertinib monotherapy remains appropriate for patients with lower-risk disease, frailty, poorer performance status, or significant comorbidities, or for those who prefer a lower treatment burden; age alone should not determine treatment choice. Post-progression therapy should be guided by repeat biopsy, plasma genotyping, and identified resistance mechanisms.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-19
DOI
https://doi.org/10.3390/biomedicines14112688
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Osimertinib, Osimertinib Plus Chemotherapy, and Amivantamab Plus Lazertinib with Focus on Efficacy, Safety, Acquired Resistance, and Health-Economic Considerations

Amichay Meirovitz, Walid Shalata, Keren Rouvinov, Sondos Shalata et al.
Biomedicines
Lung Cancer Treatments and Mutations
article

First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Osimertinib, Osimertinib Plus Chemotherapy, and Amivantamab Plus Lazertinib with Focus on Efficacy, Safety, Acquired Resistance, and Health-Economic Considerations

Amichay Meirovitz, Walid Shalata, Keren Rouvinov, Sondos Shalata, Lena Tourkey, Arina Soklakova, Omar Abu Saleh, Lama Tourkey, Nashat Abu Yasin, Noa Shrem, Marios Ghantus, Amir Lovker, Roxana Grinberg
article en

Abstract

Background: Treatment of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) has evolved from first-generation tyrosine kinase inhibitors (TKIs) to third-generation osimertinib and, more recently, to intensified first-line regimens. Osimertinib monotherapy remains effective and comparatively tolerable, while osimertinib plus platinum-pemetrexed and amivantamab plus lazertinib improve progression-free and overall survival at the cost of greater toxicity. This article evaluates current first- and subsequent-line treatment strategies for advanced NSCLC harboring common sensitizing EGFR mutations (exon 19 deletions or exon 21 L858R substitutions), with particular attention to efficacy, toxicity, resistance mechanisms, and patient selection. Methods: A structured assessment of phase III randomized trials, published network meta-analyses and indirect comparisons, and resistance-focused literature was conducted to compare efficacy, toxicity, resistance mechanisms, costs, and patient-selection considerations across current treatments. No original statistical analysis was performed; comparative estimates were derived from published studies. Results: First-line intensification with osimertinib plus chemotherapy or amivantamab plus lazertinib improves progression-free survival (PFS) and overall survival (OS) over osimertinib alone in EGFR-mutant NSCLC, particularly in high-risk patients, but it also increases toxicity, and resistance remains heterogeneous and may require repeat molecular profiling to guide further therapy. Published indirect comparisons have not shown a significant difference between the two intensified regimens. Conclusions: No single regimen suits all patients. Fit patients with high-risk features may derive the greatest absolute benefit from first-line intensification. Apparent differences between osimertinib plus platinum-pemetrexed and amivantamab plus lazertinib in subgroups (such as L858R or TP53 co-mutation) are based mainly on exploratory cross-trial data and do not establish superiority of either regimen. Amivantamab plus lazertinib offers a chemotherapy-free alternative with a distinct toxicity profile. Osimertinib monotherapy remains appropriate for patients with lower-risk disease, frailty, poorer performance status, or significant comorbidities, or for those who prefer a lower treatment burden; age alone should not determine treatment choice. Post-progression therapy should be guided by repeat biopsy, plasma genotyping, and identified resistance mechanisms.

BiomedicinesVol. 14(11)
Ben-Gurion University of the Negev (IL), Western Galilee Hospital (IL), Soroka Medical Center (IL), Jewish General Hospital (CA), Lady Davis Institute for Medical Research (CA), McGill University (CA)
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon